25 XP   0   0   10

Kymera Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Kymera Therapeutics Inc together

PenkeI guess you are interested in Kymera Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kymera Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kymera Therapeutics Inc

I send you an email if I find something interesting about Kymera Therapeutics Inc.

Quick analysis of Kymera Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Kymera Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.46
Expected worth in 1 year
$4.91
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
$-1.56
Return On Investment
-3.9%

For what price can you sell your share?

Current Price per Share
$40.17
Expected price per share
$34.50 - $45.31
How sure are you?
50%

1. Valuation of Kymera Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$40.17

Intrinsic Value Per Share

$-3.73 - $-3.48

Total Value Per Share

$2.73 - $2.98

2. Growth of Kymera Therapeutics Inc (5 min.)




Is Kymera Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$394.9m$457.4m-$35.4m-8.4%

How much money is Kymera Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$35.6m-$37.8m$2.1m6.1%
Net Profit Margin-442.4%-341.3%--

How much money comes from the company's main activities?

3. Financial Health of Kymera Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#141 / 1031

Most Revenue
#220 / 1031

Most Profit
#870 / 1031

Most Efficient
#745 / 1031

What can you expect buying and holding a share of Kymera Therapeutics Inc? (5 min.)

Welcome investor! Kymera Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Kymera Therapeutics Inc.

What can you expect buying and holding a share of Kymera Therapeutics Inc?

First you should know what it really means to hold a share of Kymera Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Kymera Therapeutics Inc is $40.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kymera Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kymera Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.46. Based on the TTM, the Book Value Change Per Share is $-0.39 per quarter. Based on the YOY, the Book Value Change Per Share is $0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kymera Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.24-0.6%-0.60-1.5%-0.63-1.6%-0.44-1.1%-0.44-1.1%
Usd Book Value Change Per Share-0.010.0%-0.39-1.0%0.120.3%0.360.9%0.360.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%-0.39-1.0%0.120.3%0.360.9%0.360.9%
Usd Price Per Share25.46-23.00-27.19-28.03-28.03-
Price to Earnings Ratio-27.07--12.80--10.94--20.38--20.38-
Price-to-Total Gains Ratio-2,758.69--724.30--44.57--286.64--286.64-
Price to Book Ratio3.94-3.31-3.69-4.67-4.67-
Price-to-Total Gains Ratio-2,758.69--724.30--44.57--286.64--286.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share40.17
Number of shares24
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.390.36
Usd Total Gains Per Share-0.390.36
Gains per Quarter (24 shares)-9.348.62
Gains per Year (24 shares)-37.3834.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-37-4703424
20-75-8406958
30-112-121010392
40-150-1580138126
50-187-1950172160
60-224-2320207194
70-262-2690241228
80-299-3060276262
90-336-3430310296
100-374-3800345330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.012.02.022.2%4.012.02.022.2%4.012.02.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.012.02.022.2%4.012.02.022.2%4.012.02.022.2%

Fundamentals of Kymera Therapeutics Inc

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-20 22:15:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kymera Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kymera Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -30.0% means that $-0.30 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kymera Therapeutics Inc:

  • The MRQ is -30.0%. The company is making a huge loss. -2
  • The TTM is -442.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-442.4%+412.4%
TTM-442.4%YOY-341.3%-101.2%
TTM-442.4%5Y-357.2%-85.2%
5Y-357.2%10Y-357.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-171.8%+141.8%
TTM-442.4%-205.8%-236.6%
YOY-341.3%-262.1%-79.2%
5Y-357.2%-455.6%+98.4%
10Y-357.2%-589.0%+231.8%
1.1.2. Return on Assets

Shows how efficient Kymera Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • -2.5% Return on Assets means that Kymera Therapeutics Inc generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kymera Therapeutics Inc:

  • The MRQ is -2.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.5%TTM-6.2%+3.7%
TTM-6.2%YOY-6.5%+0.4%
TTM-6.2%5Y-5.6%-0.6%
5Y-5.6%10Y-5.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.5%-12.5%+10.0%
TTM-6.2%-12.2%+6.0%
YOY-6.5%-11.2%+4.7%
5Y-5.6%-13.4%+7.8%
10Y-5.6%-14.7%+9.1%
1.1.3. Return on Equity

Shows how efficient Kymera Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • -3.6% Return on Equity means Kymera Therapeutics Inc generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kymera Therapeutics Inc:

  • The MRQ is -3.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.6%TTM-8.5%+4.8%
TTM-8.5%YOY-8.4%-0.1%
TTM-8.5%5Y-6.4%-2.0%
5Y-6.4%10Y-6.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.6%-15.8%+12.2%
TTM-8.5%-15.7%+7.2%
YOY-8.4%-13.9%+5.5%
5Y-6.4%-18.3%+11.9%
10Y-6.4%-19.2%+12.8%

1.2. Operating Efficiency of Kymera Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kymera Therapeutics Inc is operating .

  • Measures how much profit Kymera Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -29.9% means the company generated $-0.30  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kymera Therapeutics Inc:

  • The MRQ is -29.9%. The company is operating very inefficient. -2
  • The TTM is -494.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-29.9%TTM-494.7%+464.8%
TTM-494.7%YOY-361.9%-132.8%
TTM-494.7%5Y-373.5%-121.1%
5Y-373.5%10Y-373.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.9%-299.1%+269.2%
TTM-494.7%-210.1%-284.6%
YOY-361.9%-279.7%-82.2%
5Y-373.5%-459.9%+86.4%
10Y-373.5%-596.9%+223.4%
1.2.2. Operating Ratio

Measures how efficient Kymera Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are $1.42 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kymera Therapeutics Inc:

  • The MRQ is 1.421. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.085. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.421TTM6.085-4.664
TTM6.085YOY4.653+1.433
TTM6.0855Y4.816+1.269
5Y4.81610Y4.8160.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4212.861-1.440
TTM6.0853.193+2.892
YOY4.6533.615+1.038
5Y4.8165.560-0.744
10Y4.8167.396-2.580

1.3. Liquidity of Kymera Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kymera Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.73 means the company has $4.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kymera Therapeutics Inc:

  • The MRQ is 4.730. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.478. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.730TTM5.478-0.748
TTM5.478YOY5.938-0.460
TTM5.4785Y4.543+0.935
5Y4.54310Y4.5430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7303.986+0.744
TTM5.4784.440+1.038
YOY5.9385.552+0.386
5Y4.5436.158-1.615
10Y4.5436.492-1.949
1.3.2. Quick Ratio

Measures if Kymera Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.69 means the company can pay off $7.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kymera Therapeutics Inc:

  • The MRQ is 7.685. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.345. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.685TTM9.345-1.660
TTM9.345YOY10.104-0.759
TTM9.3455Y7.166+2.179
5Y7.16610Y7.1660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6853.638+4.047
TTM9.3454.168+5.177
YOY10.1045.515+4.589
5Y7.1666.012+1.154
10Y7.1666.209+0.957

1.4. Solvency of Kymera Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kymera Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kymera Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.31 means that Kymera Therapeutics Inc assets are financed with 31.4% credit (debt) and the remaining percentage (100% - 31.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kymera Therapeutics Inc:

  • The MRQ is 0.314. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.274. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.274+0.040
TTM0.274YOY0.216+0.059
TTM0.2745Y0.433-0.159
5Y0.43310Y0.4330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3140.335-0.021
TTM0.2740.330-0.056
YOY0.2160.267-0.051
5Y0.4330.367+0.066
10Y0.4330.378+0.055
1.4.2. Debt to Equity Ratio

Measures if Kymera Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 45.8% means that company has $0.46 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kymera Therapeutics Inc:

  • The MRQ is 0.458. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.380. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.458TTM0.380+0.078
TTM0.380YOY0.276+0.104
TTM0.3805Y0.379+0.001
5Y0.37910Y0.3790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4580.376+0.082
TTM0.3800.398-0.018
YOY0.2760.334-0.058
5Y0.3790.429-0.050
10Y0.3790.476-0.097

2. Market Valuation of Kymera Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kymera Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Kymera Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -27.07 means the investor is paying $-27.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kymera Therapeutics Inc:

  • The EOD is -42.714. Based on the earnings, the company is expensive. -2
  • The MRQ is -27.072. Based on the earnings, the company is expensive. -2
  • The TTM is -12.801. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-42.714MRQ-27.072-15.642
MRQ-27.072TTM-12.801-14.272
TTM-12.801YOY-10.942-1.858
TTM-12.8015Y-20.385+7.584
5Y-20.38510Y-20.3850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-42.714-2.643-40.071
MRQ-27.072-2.418-24.654
TTM-12.801-2.742-10.059
YOY-10.942-4.123-6.819
5Y-20.385-6.257-14.128
10Y-20.385-6.478-13.907
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kymera Therapeutics Inc:

  • The EOD is -171.429. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -108.653. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -32.766. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-171.429MRQ-108.653-62.776
MRQ-108.653TTM-32.766-75.886
TTM-32.766YOY-10.587-22.179
TTM-32.7665Y-17.340-15.426
5Y-17.34010Y-17.3400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-171.429-3.244-168.185
MRQ-108.653-2.939-105.714
TTM-32.766-3.478-29.288
YOY-10.587-5.592-4.995
5Y-17.340-8.473-8.867
10Y-17.340-8.881-8.459
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kymera Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.94 means the investor is paying $3.94 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kymera Therapeutics Inc:

  • The EOD is 6.215. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.939. Based on the equity, the company is fair priced.
  • The TTM is 3.308. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD6.215MRQ3.939+2.276
MRQ3.939TTM3.308+0.631
TTM3.308YOY3.691-0.382
TTM3.3085Y4.668-1.360
5Y4.66810Y4.6680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.2152.124+4.091
MRQ3.9392.041+1.898
TTM3.3082.118+1.190
YOY3.6912.915+0.776
5Y4.6683.682+0.986
10Y4.6684.114+0.554
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kymera Therapeutics Inc.

3.1. Institutions holding Kymera Therapeutics Inc

Institutions are holding 102.582% of the shares of Kymera Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP9.81141.7375995928124552826.2194
2023-12-31T. Rowe Price Associates, Inc.8.73110.018353357122782875.5025
2023-12-31Wellington Management Company LLP7.87990.02294815558-7771-0.1611
2023-09-30Bvf Inc7.75471.7763473900400
2023-12-31Vanguard Group Inc6.54140.00223997564723511.8432
2023-12-31venBio Select Advisor LLC6.17721.32763775000-80000-2.0752
2023-12-31BlackRock Inc5.83620.002335666112087276.216
2023-12-31Artal Group S A4.14122.142253073572538940.1801
2023-12-31State Street Corporation3.09970.00241894279-91607-4.6129
2023-09-30Redmile Group, LLC3.05751.2357186850700
2023-12-31Rock Springs Capital Management LP2.49090.95411522238178871.189
2023-12-31Goldman Sachs Group Inc2.20790.003113493101144602559.1389
2023-12-31T. Rowe Price Investment Management,Inc.2.12060.02151295943-314553-19.5314
2023-12-31Aquilo Capital Management, LLC1.442213.98478813379911812.6714
2023-12-31Geode Capital Management, LLC1.44080.0024880515462885.5486
2023-12-31FMR Inc0.87480.0011534600-335947-38.5903
2023-12-31Dimensional Fund Advisors, Inc.0.87340.004533723-121504-18.5438
2023-12-31JPMorgan Chase & Co0.83820.0013512246-109746-17.6443
2023-12-31NORGES BANK0.82490.0022504083282066127.047
2023-12-31Massachusetts Financial Services Company0.75710.0038462675-858-0.1851
Total 76.901123.244946995568+3058257+6.5%

3.2. Funds holding Kymera Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31T. Rowe Price New Horizons4.50710.28342754382769952.8758
2023-12-31US Small-Cap Growth II Equity Comp4.50710.28252754382769952.8758
2023-12-31Vanguard Health Care Inv2.35960.0791144201900
2024-02-29Vanguard Total Stock Mkt Idx Inv2.22460.0037135951100
2024-02-29SPDR® S&P Biotech ETF1.84850.60911129622211201.9053
2024-02-29Vanguard Small Cap Index1.82630.03391116080103900.9397
2023-12-31Vanguard Explorer Inv1.8220.1326111344500
2023-12-31T. Rowe Price Health Sciences1.61940.171398963410374611.711
2024-02-29iShares Russell 2000 ETF1.51070.0632923192-151-0.0164
2024-02-29Vanguard Small Cap Growth Index Inv1.02360.0765625529104231.6945
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.9820.0251600141-3830-0.6341
2023-12-31T. Rowe Price New Horizons Tr-Z0.75580.2717461910186324.2032
2023-12-31T. Rowe Price Small-Cap Value0.66250.0975404853-228700-36.098
2023-09-30UBS: US Equity Small Cap Growth0.65630.259640110500
2024-01-31Fidelity Select Biotechnology0.63240.2746386441-145872-27.4034
2023-12-31Fidelity Small Cap Index0.620.03837889147121.2593
2024-02-29iShares Biotechnology ETF0.60470.2075369540-1665-0.4485
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.5820.116235570000
2024-02-29iShares Russell 2000 Growth ETF0.54670.1257334081-388-0.116
2024-01-31Fidelity Growth Compy Commingled Pl O0.47290.01322890172890170
Total 29.76423.164418189475+231424+1.3%

3.3. Insider Transactions

Insiders are holding 1.38% of the shares of Kymera Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-15Bruce BoothSELL7176440.46
2024-03-13Bruce BoothSELL13925542.23
2024-03-13Venture Fund X L.p. AtlasSELL11509042.23
2024-03-11Bruce BoothSELL5118442.85
2024-03-11Venture Fund X L.p. AtlasSELL4230242.85
2024-03-04Bruce N JacobsSELL393441.86
2024-02-21Jeffrey W. AlbersSELL438539.05
2024-02-09Jared GollobSELL4613735.5
2024-01-23Jeffrey W. AlbersSELL1000030.05
2024-01-04Ellen ChiniaraSELL329522.58
2023-11-02Bvf Partners L P/ilBUY21640611.64

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kymera Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.009-0.389+4119%0.125-107%0.359-103%0.359-103%
Book Value Per Share--6.4636.905-6%7.485-14%5.025+29%5.025+29%
Current Ratio--4.7305.478-14%5.938-20%4.543+4%4.543+4%
Debt To Asset Ratio--0.3140.274+14%0.216+46%0.433-28%0.433-28%
Debt To Equity Ratio--0.4580.380+20%0.276+66%0.379+21%0.379+21%
Dividend Per Share----0%-0%-0%-0%
Eps---0.235-0.601+156%-0.633+169%-0.439+87%-0.439+87%
Free Cash Flow Per Share---0.059-0.562+859%-0.638+989%-0.335+472%-0.335+472%
Free Cash Flow To Equity Per Share---0.027-0.545+1922%-0.012-56%0.318-108%0.318-108%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.478--------
Intrinsic Value_10Y_min---3.731--------
Intrinsic Value_1Y_max---2.030--------
Intrinsic Value_1Y_min---1.995--------
Intrinsic Value_3Y_max---4.818--------
Intrinsic Value_3Y_min---4.626--------
Intrinsic Value_5Y_max---6.061--------
Intrinsic Value_5Y_min---5.736--------
Market Cap2454856989.000+37%1555903882.0001405263541.500+11%1661321564.500-6%1713232558.556-9%1713232558.556-9%
Net Profit Margin---0.300-4.424+1374%-3.413+1037%-3.572+1090%-3.572+1090%
Operating Margin---0.299-4.947+1555%-3.619+1110%-3.735+1149%-3.735+1149%
Operating Ratio--1.4216.085-77%4.653-69%4.816-70%4.816-70%
Pb Ratio6.215+37%3.9393.308+19%3.691+7%4.668-16%4.668-16%
Pe Ratio-42.714-58%-27.072-12.801-53%-10.942-60%-20.385-25%-20.385-25%
Price Per Share40.170+37%25.46022.995+11%27.185-6%28.034-9%28.034-9%
Price To Free Cash Flow Ratio-171.429-58%-108.653-32.766-70%-10.587-90%-17.340-84%-17.340-84%
Price To Total Gains Ratio-4352.583-58%-2758.695-724.296-74%-44.569-98%-286.638-90%-286.638-90%
Quick Ratio--7.6859.345-18%10.104-24%7.166+7%7.166+7%
Return On Assets---0.025-0.062+147%-0.065+162%-0.056+124%-0.056+124%
Return On Equity---0.036-0.085+133%-0.084+130%-0.064+76%-0.064+76%
Total Gains Per Share---0.009-0.389+4119%0.125-107%0.359-103%0.359-103%
Usd Book Value--394971000.000421984750.000-6%457426750.000-14%307087444.444+29%307087444.444+29%
Usd Book Value Change Per Share---0.009-0.389+4119%0.125-107%0.359-103%0.359-103%
Usd Book Value Per Share--6.4636.905-6%7.485-14%5.025+29%5.025+29%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.235-0.601+156%-0.633+169%-0.439+87%-0.439+87%
Usd Free Cash Flow---3580000.000-34326500.000+859%-38980250.000+989%-20467833.333+472%-20467833.333+472%
Usd Free Cash Flow Per Share---0.059-0.562+859%-0.638+989%-0.335+472%-0.335+472%
Usd Free Cash Flow To Equity Per Share---0.027-0.545+1922%-0.012-56%0.318-108%0.318-108%
Usd Market Cap2454856989.000+37%1555903882.0001405263541.500+11%1661321564.500-6%1713232558.556-9%1713232558.556-9%
Usd Price Per Share40.170+37%25.46022.995+11%27.185-6%28.034-9%28.034-9%
Usd Profit---14368000.000-35654750.000+148%-37827000.000+163%-25703888.889+79%-25703888.889+79%
Usd Revenue--47885000.00019648000.000+144%11706500.000+309%13059277.778+267%13059277.778+267%
Usd Total Gains Per Share---0.009-0.389+4119%0.125-107%0.359-103%0.359-103%
 EOD+5 -3MRQTTM+23 -10YOY+15 -185Y+22 -1110Y+22 -11

4.2. Fundamental Score

Let's check the fundamental score of Kymera Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-42.714
Price to Book Ratio (EOD)Between0-16.215
Net Profit Margin (MRQ)Greater than0-0.300
Operating Margin (MRQ)Greater than0-0.299
Quick Ratio (MRQ)Greater than17.685
Current Ratio (MRQ)Greater than14.730
Debt to Asset Ratio (MRQ)Less than10.314
Debt to Equity Ratio (MRQ)Less than10.458
Return on Equity (MRQ)Greater than0.15-0.036
Return on Assets (MRQ)Greater than0.05-0.025
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Kymera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.885
Ma 20Greater thanMa 5041.262
Ma 50Greater thanMa 10037.436
Ma 100Greater thanMa 20029.745
OpenGreater thanClose39.980
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets575,759
Total Liabilities180,788
Total Stockholder Equity394,971
 As reported
Total Liabilities 180,788
Total Stockholder Equity+ 394,971
Total Assets = 575,759

Assets

Total Assets575,759
Total Current Assets405,317
Long-term Assets170,442
Total Current Assets
Cash And Cash Equivalents 109,966
Short-term Investments 264,915
Net Receivables 18,762
Other Current Assets 11,674
Total Current Assets  (as reported)405,317
Total Current Assets  (calculated)405,317
+/-0
Long-term Assets
Property Plant Equipment 101,079
Long Term Investments 61,434
Long-term Assets Other 7,929
Long-term Assets  (as reported)170,442
Long-term Assets  (calculated)170,442
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities85,691
Long-term Liabilities95,097
Total Stockholder Equity394,971
Total Current Liabilities
Short-term Debt 6,345
Accounts payable 7,075
Other Current Liabilities 34,388
Total Current Liabilities  (as reported)85,691
Total Current Liabilities  (calculated)47,808
+/- 37,883
Long-term Liabilities
Capital Lease Obligations 84,674
Long-term Liabilities  (as reported)95,097
Long-term Liabilities  (calculated)84,674
+/- 10,423
Total Stockholder Equity
Common Stock6
Retained Earnings -530,752
Accumulated Other Comprehensive Income -552
Other Stockholders Equity 926,269
Total Stockholder Equity (as reported)394,971
Total Stockholder Equity (calculated)394,971
+/-0
Other
Capital Stock6
Cash and Short Term Investments 374,881
Common Stock Shares Outstanding 58,522
Current Deferred Revenue37,883
Liabilities and Stockholders Equity 575,759
Net Debt -25,292
Net Invested Capital 394,971
Net Working Capital 319,626
Property Plant and Equipment Gross 111,519
Short Long Term Debt Total 84,674



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
0
116,702
0
181,109
507,361
487,175
464,552
434,386
642,453
605,905
563,060
523,421
638,472
603,134
613,905
581,945
552,378
575,759
575,759552,378581,945613,905603,134638,472523,421563,060605,905642,453434,386464,552487,175507,361181,1090116,7020
   > Total Current Assets 
92,845
92,845
158,301
158,301
297,364
302,339
340,791
364,806
543,731
567,605
431,382
402,770
494,022
559,494
515,894
385,402
375,694
405,317
405,317375,694385,402515,894559,494494,022402,770431,382567,605543,731364,806340,791302,339297,364158,301158,30192,84592,845
       Cash And Cash Equivalents 
0
76,015
0
60,971
54,593
31,004
53,098
84,903
156,819
47,976
33,733
76,914
155,658
68,395
50,152
52,386
81,051
109,966
109,96681,05152,38650,15268,395155,65876,91433,73347,976156,81984,90353,09831,00454,59360,971076,0150
       Short-term Investments 
0
15,942
0
94,994
239,248
265,198
280,439
274,204
379,567
394,442
387,079
315,395
326,250
338,771
346,725
315,188
276,774
264,915
264,915276,774315,188346,725338,771326,250315,395387,079394,442379,567274,204280,439265,198239,24894,994015,9420
       Net Receivables 
0
0
0
0
577
1,433
1,734
904
1,573
135
1,263
2,370
2,882
2,537
3,320
4,122
3,778
18,762
18,7623,7784,1223,3202,5372,8822,3701,2631351,5739041,7341,4335770000
       Other Current Assets 
0
888
200
2,336
2,946
4,704
5,520
4,795
5,772
8,720
9,307
8,091
9,232
9,713
11,353
13,706
14,091
11,674
11,67414,09113,70611,3539,7139,2328,0919,3078,7205,7724,7955,5204,7042,9462,3362008880
   > Long-term Assets 
0
23,857
0
22,808
209,997
184,836
123,761
69,580
98,722
38,300
131,678
120,651
144,450
43,640
98,011
196,543
176,684
170,442
170,442176,684196,54398,01143,640144,450120,651131,67838,30098,72269,580123,761184,836209,99722,808023,8570
       Property Plant Equipment 
22,083
22,083
20,285
20,285
20,943
10,841
20,502
21,766
21,724
11,881
21,066
21,929
21,617
13,334
74,036
83,181
91,100
101,079
101,07991,10083,18174,03613,33421,61721,92921,06611,88121,72421,76620,50210,84120,94320,28520,28522,08322,083
       Long Term Investments 
0
0
0
0
187,464
162,531
101,639
45,305
74,692
125,187
102,478
90,182
113,701
152,328
119,017
104,759
76,988
61,434
61,43476,988104,759119,017152,328113,70190,182102,478125,18774,69245,305101,639162,531187,4640000
       Long-term Assets Other 
0
1,774
0
2,523
1,590
11,464
1,620
2,509
2,306
-98,768
8,134
8,540
9,132
-122,022
-95,042
8,603
8,596
7,929
7,9298,5968,603-95,042-122,0229,1328,5408,134-98,7682,3062,5091,62011,4641,5902,52301,7740
> Total Liabilities 
0
191,108
0
77,066
212,676
203,287
189,305
176,282
159,318
146,267
134,340
125,470
125,587
112,983
151,900
146,517
156,843
180,788
180,788156,843146,517151,900112,983125,587125,470134,340146,267159,318176,282189,305203,287212,67677,0660191,1080
   > Total Current Liabilities 
34,570
34,570
42,680
42,680
107,286
110,617
110,137
108,685
94,493
101,034
88,339
87,500
91,124
63,260
123,543
54,602
63,166
85,691
85,69163,16654,602123,54363,26091,12487,50088,339101,03494,493108,685110,137110,617107,28642,68042,68034,57034,570
       Short-term Debt 
0
3,377
0
3,705
2,733
3,261
3,048
3,463
3,632
3,599
3,567
3,656
3,619
3,943
66,429
3,797
3,595
6,345
6,3453,5953,79766,4293,9433,6193,6563,5673,5993,6323,4633,0483,2612,7333,70503,3770
       Accounts payable 
3,276
3,276
3,982
3,982
3,979
4,368
8,348
8,177
5,033
4,005
2,567
2,374
6,327
4,335
6,483
3,745
4,978
7,075
7,0754,9783,7456,4834,3356,3272,3742,5674,0055,0338,1778,3484,3683,9793,9823,9823,2763,276
       Other Current Liabilities 
23,349
4,568
27,289
7,704
8,563
-67,402
10,829
14,782
19,594
-7,604
21,353
22,010
25,402
-8,278
-6,483
22,758
27,241
34,388
34,38827,24122,758-6,483-8,27825,40222,01021,353-7,60419,59414,78210,829-67,4028,5637,70427,2894,56823,349
   > Long-term Liabilities 
0
156,538
0
34,386
105,390
92,670
79,168
67,597
64,825
45,233
46,001
37,970
34,463
49,723
28,357
91,915
93,677
95,097
95,09793,67791,91528,35749,72334,46337,97046,00145,23364,82567,59779,16892,670105,39034,3860156,5380
       Capital Lease Obligations Min Short Term Debt
0
17,816
0
15,399
15,082
14,732
14,422
14,841
14,810
14,364
13,905
13,635
13,121
13,392
0
71,264
77,248
78,329
78,32977,24871,264013,39213,12113,63513,90514,36414,81014,84114,42214,73215,08215,399017,8160
       Long-term Liabilities Other 
0
0
0
0
0
100
92
84
64,825
53,725
46,001
264
256
248
28,357
230
8
0
0823028,35724825626446,00153,72564,825849210000000
> Total Stockholder Equity
0
-74,406
0
104,043
294,685
283,888
275,247
258,104
483,135
459,638
428,720
397,951
512,885
490,151
462,005
435,428
395,535
394,971
394,971395,535435,428462,005490,151512,885397,951428,720459,638483,135258,104275,247283,888294,685104,0430-74,4060
   Common Stock
0
0
0
3
4
4
4
5
5
5
5
5
6
6
6
6
6
6
666666555554443000
   Retained Earnings Total Equity000-424,718-383,790-348,925-305,923-265,666-228,982-195,082-166,500-141,840-128,76500000
   Accumulated Other Comprehensive Income 
0
6
0
31
-164
-128
-13
-3,176
-146
-660
-3,216
-3,983
-5,913
-4,949
-3,038
-3,635
-2,450
-552
-552-2,450-3,635-3,038-4,949-5,913-3,983-3,216-660-146-3,176-13-128-16431060
   Capital Surplus 
0
0
0
0
0
412,777
417,096
424,599
678,358
689,275
697,597
707,852
867,717
878,884
889,755
0
0
0
000889,755878,884867,717707,852697,597689,275678,358424,599417,096412,77700000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
6
2,044
31
212,103
-96,436
412,777
417,096
424,599
678,358
689,275
697,597
707,852
867,717
878,884
889,755
902,574
914,363
926,269
926,269914,363902,574889,755878,884867,717707,852697,597689,275678,358424,599417,096412,777-96,436212,103312,0446



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue78,592
Cost of Revenue-3,565
Gross Profit75,02775,027
 
Operating Income (+$)
Gross Profit75,027
Operating Expense-244,122
Operating Income-165,530-169,095
 
Operating Expense (+$)
Research Development189,081
Selling General Administrative55,041
Selling And Marketing Expenses0
Operating Expense244,122244,122
 
Net Interest Income (+$)
Interest Income18,764
Interest Expense-196
Other Finance Cost-0
Net Interest Income18,568
 
Pretax Income (+$)
Operating Income-165,530
Net Interest Income18,568
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-146,962-184,098
EBIT - interestExpense = -146,962
-128,198
-146,766
Interest Expense196
Earnings Before Interest and Taxes (EBIT)-146,766-146,766
Earnings Before Interest and Taxes (EBITDA)-143,201
 
After tax Income (+$)
Income Before Tax-146,962
Tax Provision-0
Net Income From Continuing Ops-146,962-146,962
Net Income-146,962
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses244,122
Total Other Income/Expenses Net18,568-18,568
 

Technical Analysis of Kymera Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kymera Therapeutics Inc. The general trend of Kymera Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kymera Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kymera Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 41.03 < 45.31.

The bearish price targets are: 39.50 > 38.75 > 34.50.

Tweet this
Kymera Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kymera Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kymera Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kymera Therapeutics Inc. The current macd is 0.50521256.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kymera Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Kymera Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Kymera Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kymera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartKymera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kymera Therapeutics Inc. The current adx is 26.62.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kymera Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Kymera Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kymera Therapeutics Inc. The current sar is 41.33.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kymera Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kymera Therapeutics Inc. The current rsi is 51.88. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Kymera Therapeutics Inc Daily Relative Strength Index (RSI) ChartKymera Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kymera Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kymera Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Kymera Therapeutics Inc Daily Stochastic Oscillator ChartKymera Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kymera Therapeutics Inc. The current cci is -83.94519131.

Kymera Therapeutics Inc Daily Commodity Channel Index (CCI) ChartKymera Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kymera Therapeutics Inc. The current cmo is -3.86973566.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kymera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartKymera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kymera Therapeutics Inc. The current willr is -74.08759124.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kymera Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kymera Therapeutics Inc Daily Williams %R ChartKymera Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kymera Therapeutics Inc.

Kymera Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kymera Therapeutics Inc. The current atr is 1.88784589.

Kymera Therapeutics Inc Daily Average True Range (ATR) ChartKymera Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kymera Therapeutics Inc. The current obv is 2,893,784.

Kymera Therapeutics Inc Daily On-Balance Volume (OBV) ChartKymera Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kymera Therapeutics Inc. The current mfi is 46.82.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kymera Therapeutics Inc Daily Money Flow Index (MFI) ChartKymera Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kymera Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Kymera Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kymera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.885
Ma 20Greater thanMa 5041.262
Ma 50Greater thanMa 10037.436
Ma 100Greater thanMa 20029.745
OpenGreater thanClose39.980
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kymera Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Kymera Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kymera Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kymera Therapeutics Inc

I send you an email if I find something interesting about Kymera Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kymera Therapeutics Inc.

Receive notifications about Kymera Therapeutics Inc in your mailbox!